January 2023 in “Revista Eletrônica Acervo Saúde” Oral Minoxidil effectively treats hair loss with increased hair growth as a side effect, and low doses are generally safe.
June 2023 in “Journal of Cosmetic Dermatology” Finasteride 5mg daily is the most effective for female pattern hair loss, with higher doses of treatments generally more effective.
February 2024 in “Actas Dermo-Sifiliográficas” Dermatologists recommend oral dutasteride for male hair loss, low-dose oral minoxidil for female hair loss, and a multidisciplinary approach for young patients, with caution during pregnancy.
1 citations
,
July 2022 in “JEADV Clinical Practice” New and existing treatments for hair loss show promise, with some being more effective for men and others for women.
July 2025 in “Journal of Investigative Dermatology” AMP-303 safely increases hair growth in men with hair loss.
2 citations
,
July 2009 in “Pharmacognosy Research” A herbal mix with chickpea, holy basil, and nut grass extracts grew rat hair well, similar to a common hair growth drug.
16 citations
,
March 2009 in “Skin Pharmacology and Physiology” SEPA™ enhances the effectiveness of minoxidil in stimulating hair growth, working faster and better than Rogaine® TS, with no significant side effects.
4 citations
,
January 2009 in “International journal of trichology” Minoxidil topical foam is a better, less irritating treatment for hair loss.
March 1990 in “Journal of Dermatological Science” June 2023 in “Zenodo (CERN European Organization for Nuclear Research)” 11 citations
,
March 2021 in “Cleveland Clinic Journal of Medicine” Treating hair loss in both men and women is effective and improves quality of life.
13 citations
,
May 2015 in “Journal of The American Academy of Dermatology” Oral minoxidil improves hair growth in men with hair loss, but caution needed for those with heart issues.
June 2025 in “Journal of the Pakistan Medical Association” 2dDR may help regrow hair in male pattern baldness.
December 2025 in “Zenodo (CERN European Organization for Nuclear Research)” Hair loss is caused by nutritional deficiencies, hormonal imbalances, and stress, with treatments like minoxidil and hair transplants available.
June 2025 in “Journal of the American Academy of Dermatology”
September 2004 in “PubMed” Androgenetic alopecia, or hair loss, is influenced by hormones and genetics, and can be treated with medications like minoxidil, finasteride, or hormone therapy, with effectiveness evaluated after 6 months.
November 2025 in “Zenodo (CERN European Organization for Nuclear Research)” PRP may be more effective and satisfying for hair regrowth than minoxidil, with similar safety.
15 citations
,
April 2002 in “PubMed” Finasteride effectively treats male pattern hair loss without serious side effects.
January 2014 in “프로그램북(구 초록집)” 5AR inhibitors like finasteride and dutasteride improve hair growth and slow hair loss in male pattern baldness.
The new treatment regimen was effective in promoting significant hair growth in all 15 male patients with androgenic alopecia.
19 citations
,
September 2014 in “British Journal of Dermatology” Minoxidil foam 5% effectively treats hair loss in both frontal and vertex scalp regions.
24 citations
,
May 2013 in “Drug Design Development and Therapy” Multimodal minoxidil microemulsion is more effective in treating hair loss than minoxidil alone.
February 2022 in “International Journal of Research in Dermatology” Topical minoxidil is the primary treatment for female pattern hair loss in India.
September 2025 in “Journal of Dermatology Research Reviews & Reports” Rigenera® effectively improves hair condition in Androgenetic Alopecia, and HairMetrix® tracks progress well.
March 2008 in “Hair transplant forum international” 22 citations
,
September 2017 in “Skin appendage disorders” Ruxolitinib helped a man regrow his beard after years of hair loss.
Hair loss should be medically treated, as non-medical treatments are ineffective and hair loss can indicate serious health issues.
July 2022 in “Zenodo (CERN European Organization for Nuclear Research)” July 2022 in “Zenodo (CERN European Organization for Nuclear Research)”